Jellison House

Jellison House is a SAMHSA-registered addiction-treatment facility located at Johnston, RI. The facility offers specific levels of care: Inpatient, Dual Dx. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Jellison House

The facility's documented care levels are The facility offers specific levels of care: Inpatient, Dual Dx. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care Jellison House provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Jellison House accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Specialty programming

The facility's documented specialty programming includes: Adult men, Criminal justice (other than DUI/DWI)/Forensic clients, Clients with co-occurring mental and substance use disorders. Evaluation of specialty-program alignment requires documented review of clinical team credentials, specialty-specific programming hours, and integrated assessment protocols. Specialty designation without documented clinical infrastructure is a recognized marketing pattern in the sector.

Before you call

Pre-admission due-diligence for Jellison House: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via RI behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Jellison House offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.